AveXis (AVXS) Given New $152.00 Price Target at Barclays

AveXis (NASDAQ:AVXS) had its price objective hoisted by equities research analysts at Barclays from $124.00 to $152.00 in a research note issued on Friday. The firm currently has an “overweight” rating on the stock. Barclays’ price target would indicate a potential upside of 38.76% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on AVXS. Canaccord Genuity set a $110.00 price objective on shares of AveXis and gave the stock a “hold” rating in a research report on Friday, January 5th. Zacks Investment Research raised shares of AveXis from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Jefferies Group lifted their price objective on shares of AveXis to $118.00 and gave the stock a “buy” rating in a research report on Thursday, October 12th. Morgan Stanley set a $120.00 price objective on shares of AveXis and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, UBS Group set a $122.00 price objective on shares of AveXis and gave the stock a “buy” rating in a research report on Friday, January 5th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $115.37.

AveXis (NASDAQ:AVXS) traded up $3.35 during trading on Friday, hitting $109.54. 515,465 shares of the stock traded hands, compared to its average volume of 665,254. The stock has a market cap of $3,930.00 and a PE ratio of -19.63. AveXis has a 1-year low of $53.94 and a 1-year high of $128.00.

AveXis (NASDAQ:AVXS) last released its quarterly earnings data on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.48) by ($0.04). During the same period last year, the firm earned ($0.87) EPS. analysts anticipate that AveXis will post -6.23 earnings per share for the current year.

In other AveXis news, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction on Friday, December 1st. The shares were sold at an average price of $94.73, for a total value of $1,420,950.00. Following the transaction, the insider now directly owns 1,826,502 shares in the company, valued at $173,024,534.46. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Andrew F. Knudten sold 2,000 shares of AveXis stock in a transaction on Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the completion of the transaction, the vice president now owns 7,000 shares in the company, valued at $661,360. The disclosure for this sale can be found here. Insiders have sold a total of 57,560 shares of company stock worth $6,160,062 over the last quarter. 18.60% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtus Fund Advisers LLC increased its stake in AveXis by 123.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 5,896 shares of the company’s stock valued at $652,000 after purchasing an additional 3,258 shares during the period. Artal Group S.A. increased its stake in AveXis by 25.0% in the fourth quarter. Artal Group S.A. now owns 150,000 shares of the company’s stock valued at $16,601,000 after purchasing an additional 30,000 shares during the period. Eagle Asset Management Inc. increased its stake in AveXis by 123.4% in the fourth quarter. Eagle Asset Management Inc. now owns 354,154 shares of the company’s stock valued at $39,274,000 after purchasing an additional 195,626 shares during the period. State of Wisconsin Investment Board increased its stake in AveXis by 55.0% in the fourth quarter. State of Wisconsin Investment Board now owns 24,800 shares of the company’s stock valued at $2,745,000 after purchasing an additional 8,800 shares during the period. Finally, Advisory Research Inc. increased its stake in AveXis by 25.5% in the fourth quarter. Advisory Research Inc. now owns 16,821 shares of the company’s stock valued at $1,862,000 after purchasing an additional 3,423 shares during the period. Institutional investors own 81.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/09/avexis-avxs-given-new-152-00-price-target-at-barclays.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply